Document:

Exhibit
10.3

 

COMMON
STOCK PURCHASE AGREEMENT 

 

AGREEMENT
(this “Agreement”) entered into as of the 10th day of December, 2021, by and between Surfside Acquisition Inc.,
a Delaware corporation (the “Company”), and Ian Jacobs, an individual (the “Purchaser”).

 

WHEREAS,
the Purchaser desires to purchase, and the Company desires to sell, an aggregate of 250,000 shares (the “Shares”) of the
Company’s common stock, par value $0.0001 per share (the “Common Stock”) upon the terms and conditions hereof.

 

NOW,
THEREFORE, in consideration of the premises and the mutual agreements herein contained, the Purchaser and the Company hereby agree as
follows:

 

SECTION
1: SALE OF THE SHARES

 

1.1
Sale of the Shares. Subject to the terms and conditions hereof, the Company will sell to the Purchaser and the Purchaser will
purchase from the Company, upon the execution and delivery of this Agreement, the Shares for a purchase price equal to $25 (the “Purchase
Price”).

 

SECTION
2: CLOSING DATE; DELIVERY

 

2.1
Closing Date. The closing of the purchase and sale of the Shares hereunder (the “Closing”) shall be held immediately
following the execution and delivery of this Agreement.

 

2.2
Delivery at Closing. At the Closing, the Company will record the issuance of the Shares in the Company’s stock ledger with
respect to the Common Stock of the Company in the Purchaser’s name, against payment of the Purchase Price therefore as indicated
above.

 

SECTION
3: REPRESENTATIONS AND WARRANTIES OF PURCHASER

 

The
undersigned Purchaser hereby represents and warrants to the Company as follows:

 

3.1
Restricted Securities. None of the Shares are registered under the Securities Act of 1933, as amended (the “Securities
Act”), or any state securities laws. The Purchaser acknowledges that the Shares have not been recommended by any US Federal
or State securities commission or regulatory authority and have not confirmed the accuracy or determined the adequacy of this Agreement.
The Purchaser understands that the offering and sale of the Shares is intended to be exempt from registration under the Securities Act,
by virtue of Section 4(a)(2) thereof and, if deemed advisable by the Company, the provisions of Regulation D promulgated thereunder,
based, in part, upon the representations, warranties and agreements of the Purchaser contained in this Agreement. The Purchaser understands
that the Shares may not be sold, transferred or otherwise disposed of without registration under the Securities Act or an exemption therefrom.

 

3.2
Experience. The Purchaser has such knowledge and experience in financial and business matters that the Purchaser is capable of
evaluating the merits and risks of investment in the Company and of making an informed investment decision. The Purchaser has adequate
means of providing for the Purchaser’s current needs and possible future contingencies and the Purchaser has no need, and anticipates
no need in the foreseeable future, to sell the Shares for which the Purchaser subscribes. The Purchaser is able to bear the economic
risks of this investment and, consequently, without limiting the generality of the foregoing, the Purchaser is able to hold the Shares
for an indefinite period of time and has sufficient net worth to sustain a loss of the Purchaser’s entire investment in the Company
in the event such loss should occur. Except as otherwise indicated herein, the Purchaser is the sole party in interest as to its investment
in the Company, and it is acquiring the Shares solely for investment for the Purchaser’s own account and has no present agreement,
understanding or arrangement to subdivide, sell, assign, transfer or otherwise dispose of all or any part of the Shares subscribed for
to any other person.

 

     

     

    

 

3.3
Investment; Access to Data. The Purchaser has carefully reviewed and understands the risks of, and other considerations relating
to, a purchase of the Shares and an investment in the Company. The Purchaser has been furnished materials relating to the Company, the
private placement of the Common Stock or anything else that it has requested and has been afforded the opportunity to ask questions and
receive answers concerning the terms and conditions of the offering and obtain any additional information which the Company possesses
or can acquire without unreasonable effort or expense. Representatives of the Company have answered all inquiries that the Purchaser
has made of them concerning the Company, or any other matters relating to the formation and operation of the Company and the offering
and sale of the Common Stock. The Purchaser has not been furnished any offering literature other than the materials that the Company
may have provided at the request of the Purchaser; and the Purchaser has relied only on such information furnished or made available
to the Purchaser by the Company as described in this Section. The Purchaser is acquiring the Shares for investment for the Purchaser’s
own account, not as a nominee or agent and not with the view to, or for resale in connection with, any distribution thereof. The Purchaser
acknowledges that the Company is a start-up company with no current operations, assets or operating history, which may possibly cause
a loss of Purchaser’s entire investment in the Company.

 

3.4
Authorization. (a) This Agreement, upon execution and delivery thereof, will be a valid and binding obligation of Purchaser, enforceable
in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization and moratorium laws and other laws of general
application affecting enforcement of creditors’ rights generally.

 

(b)
The execution, delivery and performance by Purchaser of this Agreement and compliance therewith and the purchase and sale of the Shares
will not result in a violation of and will not conflict with, or result in a breach of, any of the terms of, or constitute a default
under, any provision of state or Federal law to which Purchaser is subject, or any mortgage, indenture, agreement, instrument, judgment,
decree, order, rule or regulation or other restriction to which the Purchaser is a party or by which the Purchaser is bound, or result
in the creation of any mortgage, pledge, lien, encumbrance or charge upon any of the properties or assets of Purchaser pursuant to any
such term.

 

3.5
Accredited Investor. Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D under the Securities Act of
1933, as amended and has executed the statement of accredited investor annexed hereto as Exhibit A.

 

SECTION
4: MISCELLANEOUS

 

4.1
Governing Law. This Agreement shall be governed in all respects by the laws of the State of Delaware, without regard to conflicts
of laws principles thereof.

 

4.2
Survival. The terms, conditions and agreements made herein shall survive the Closing.

 

4.3
Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and
be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

 

4.4
Entire Agreement; Amendment; Waiver. This Agreement constitutes the entire and full understanding and agreement between the parties
with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be amended, waived, discharged or terminated,
except by a written instrument signed by all the parties hereto.

 

4.5
Counterparts; Electronic Signature. This Agreement may be executed in any number of counterparts, each of which shall be an original,
but all of which together, shall constitute one instrument. This Agreement may be executed by facsimile or pdf signature by any party
and such signature will be deemed binding for all purposes hereof without delivery of an original signature being thereafter required.

 

[The
remainder of this page has been intentionally left blank.]

 

    2

     

    

 

IN
WITNESS WHEREOF, the undersigned have hereunto set their hands as of the day and year first written above

 

	 	SURFSIDE
    ACQUISITION INC.
	 	 
	 	By:	/s/
    Ian Jacobs
	 	 	Ian
    Jacobs
	 	 	President,
    Secretary, Chief Executive Officer,
	 	 	and
    Chief Financial Officer
	 	 	 
	 	PURCHASER
	 	 
	 	/s/
    Ian Jacobs
	 	Ian
    Jacobs

 

    3

     

    

 

Exhibit
A

 

STATEMENT
OF ACCREDITED INVESTOR

 

	To:	Surfside
    Acquisition Inc. (the “Company”)

 

Ladies
and Gentlemen:

 

The
undersigned hereby refers to the Common Stock Purchase Agreement executed and delivered to the Company by the undersigned as of the date
hereof. In connection with the subscription thereunder by the undersigned to purchase securities of the Company, the undersigned hereby
represents and warrants that such individual or entity meets at least one of the tests listed below for an “accredited investor”
(as such term is defined under Regulation D promulgated pursuant to the Securities Act of 1933, as amended).

 

“Accredited
Investors” are accorded special status under the federal securities laws. Individuals who hold certain positions with an issuer
or its affiliates, or who have certain minimum individual income or certain minimum net worth (each as described below) may qualify as
Accredited Investors. Partnerships, corporations or other entities may qualify as Accredited Investors if they fulfill certain financial
and other standards, or if all of their equity owners have incomes and/or net worth which qualify them individually as Accredited Investors,
and trusts may qualify as Accredited Investors if they meet certain financial and other tests (as described below).

 

You
may qualify as an Accredited Investor under Regulation D promulgated under the Securities Act of 1933 (the “Securities Act”)
if you meet any of the following tests (please check all that apply):

 

_____
(a) The undersigned is a natural person whose net worth, or joint net worth with spouse, at the time of purchase, exceeds $1,000,000
(excluding the value of the undersigned’s primary residence).1

 

_____
(b) The undersigned is a natural person whose individual income (excluding that of his or her spouse) exceeded $200,000 in each of
the last two years, i.e., 2019 and 2020, and who reasonably expects individual income exceeding $200,000 in the current year.

 

_____
(c) The undersigned is a natural person whose joint gross income with his or her spouse exceeded $300,000 in each of the last two years,
i.e., 2019 and 2020, and who reasonably expects joint gross income with his or her spouse exceeding $300,000 in the current year.

 

_____
(d) The undersigned is:

 

_____
(i) a bank as defined in section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in
section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity;

 

_____
(ii) a broker or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934, as amended;

 

 

1
For purposes of calculation net worth in paragraph (a) above, (i) the undersigned’s primary residence shall not be included
as an asset; (ii) indebtedness secured by the undersigned’s primary residence, up to the estimated fair market value of such primary
residence as of the date hereof, shall not be included as a liability (except that if the amount of such indebtedness outstanding as
of the date hereof exceeds the amount outstanding as of 60 days before the date hereof, other than as a result of the acquisition of
such primary residence, the amount of such excess shall be included as a liability) and (iii) indebtedness that is secured by the undersigned’s
primary residence in excess of the estimated fair market value of such primary residence as of the date hereof, shall be included as
a liability.

 

    4

     

    

 

_____
(iii) an insurance company as defined in section 2(a)(13) of the Securities Act; any investment company registered under the Investment
Company Act of 1940 or a business development company as defined in section 2(a)(48) of such act;

 

_____
(iv) any Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c) or (d) of the Small
Business Investment Act of 1958;

 

_____
(v) any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political
subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000; or

 

_____
(vi) any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974 if the investment decision is
made by a plan fiduciary, as defined in section 3(21) of such act, which is either a bank, savings and loan association, insurance company,
or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan,
with investment decisions made solely by persons that are accredited investors.

 

_____
(e) The undersigned is a private business development company as defined in section 202(a)(22) of the Investment Advisers Act of 1940.

 

_____
(f) The undersigned is a trust, and the grantor (i) has the power to revoke the trust at any time and regain title to the trust assets;
and (ii) meets the requirements of items (a) (b), or (c) above.

 

_____
(g) The undersigned is a tax-exempt organization described in Section 501(c) (3) of the Internal Revenue Code, or a corporation, Massachusetts
or similar business trust, or partnership, not formed for the specific purpose of acquiring the securities with total assets in excess
of $5,000,000.

 

_____
(h) The undersigned is a trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities,
whose purchase is directed by a person who has such knowledge and experience in financial and business matters that he or she is capable
of evaluating the merits and risks of an investment in the securities.

 

_____
(i) The undersigned is an entity in which all of the equity owners meet any of the requirements of items (a) through (h) above.

 

[SIGNATURE
PAGE FOLLOWS]

 

    5

     

    

 

Dated:
December 10, 2021

 

	 	Very
    truly yours, 
	 	 
	 	 
	 	Name
    of Individual or Entity
	 	 
	 	 
	 	Authorized
    Signature
	 	 
	 	 
	 	Address
    
	 	 
	 	 
	 	 

 

 

6EX-10.1

 Exhibit 10.1 

EXECUTIVE EMPLOYMENT AGREEMENT 

This Executive Employment Agreement (the “Agreement”), is hereby made this 20th day of March, 2022 (the “Effective Date”), between UroGen Pharma, Inc., a wholly owned subsidiary (the “Subsidiary”) of UroGen Pharma, Ltd. (the
“Parent”, and the Subsidiary and the Parent together, the “Company”), and Dong Kim (the “Executive”) (collectively, the “Parties”). 

WHEREAS, the Company desires for Executive to provide services to the Company, and wishes
to provide Executive with certain compensation and benefits in return for such employment services; and 

WHEREAS, Executive wishes to be employed by the Company and to provide personal services
to the Company in return for certain compensation and benefits; 
 NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree
as follows: 
  

	 	1.	 Employment by the Company. 

1.1 Position. Executive shall serve as the Company’s Chief Financial Officer. Executive’s
appointment to this role with the Company shall commence on March 25, 2022. During Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and
attention to the business of the Company, except for (i) approved outside activities (e.g., existing board positions, charitable activities, conferences, events, etc.), and (ii) approved vacation periods, reasonable periods of
illness or other incapacities permitted by the Company’s general employment policies, and as otherwise permitted by this Agreement. 

1.2 Duties and Location. Executive shall perform such duties as are typically required by a Chief
Financial Officer, including, in coordination with department heads, alignment and execution oversight of the Company’s key efforts in order to help meet its short and long-term business goals and objectives and measuring and reporting on the
Company’s operational performance. Executive will report to the Company’s Chief Executive Officer. Executive’s primary work location will be the Company’s Princeton, NJ office (or company’s corporate headquarters location)
and the Executive’s home office, as mutually agreed. 
 1.3 Policies and Procedures. The employment relationship
between the Parties shall be governed by the general employment policies and practices of the Company, except that when the terms of this Agreement differ from, or are in conflict with, the Company’s general employment policies or practices,
this Agreement shall control. 

  
 1 

	 	2.	 Compensation. 

2.1 Salary. For services to be rendered hereunder, Executive shall receive a base salary at the rate of
$370,000.00 per year (the “Base Salary”), subject to standard payroll deductions and withholdings and payable in accordance with the Company’s regular payroll schedule. 

2.2 Annual Bonus. Executive will be eligible for an annual discretionary bonus, with an annual target
of 50% of Executive’s Base Salary (the “Annual Bonus”), pro-rated in the case of a partial calendar year. Whether Executive receives an Annual Bonus for any given year, and the
amount of any such Annual Bonus, will be determined by the Company, with input from the Company’s Board of Directors, in its sole discretion based upon the Company’s and Executive’s achievement of goals and objectives to be determined
on an annual basis by the Company in a manner consistent with other senior management. Except as outlined in Section 5.2, Executive must remain an active employee through the end of any given calendar year in order to earn an Annual Bonus for
that year and any such bonus will be paid no later than March 15 of the following year. 
 3. Standard Company
Benefits. Executive shall be eligible to participate in all employee benefit programs which are made available generally to the Company’s U.S.-based senior executive group, on a basis comparable to such group. Employee shall be eligible to
receive two hundred hours (200) paid time off (PTO) hours annually, in accordance with the Company’s paid time off policy. The Company reserves the right to cancel or change the benefit plans or programs it offers to its employees at any
time, provided that such cancellation or change is generally applicable to the Company’s U.S.-based senior executive group participating in such plan or program. 
  

	 	4.	 Equity. 

4.1 Subject to approval by the Board of Directors of the Parent, Executive shall be granted an option
to purchase 20,000 of the Company’s ordinary shares, par value NIS 0.01 (the “Ordinary Shares”) in the Parent at the fair market value on the date of grant (the “Option”). The Options shall be governed in all
respects by the terms of the governing plan documents and option agreement between Executive and the Parent. Employee equity grants are made periodically at the discretion of the board of directors, typically on a quarterly basis. These equity
grants are intended to be a material inducement to your acceptance of the role with the company. The Option will vest over 3 years - 1/3 will vest on the first anniversary of the Vesting Commencement Date, and 1/3 of the Option will vest annually
thereafter for the remaining two (2) years. Executive will be eligible for consideration for annual grants of additional equity awards pursuant to the process applicable to other members of the executive leadership team, with the terms of any
such grants to be determined in the sole discretion of the Board. Target value of annual awards are at the discretion of the board but will target range equal to target bonus value. i.e. 50% of annual salary. 

  
 2 

	 	5.	 Termination of Employment; Severance. 

5.1 At-Will Employment. Executive’s employment relationship is at-will. Either Executive or the Company may terminate the employment relationship at any time, with or without Cause or advance notice. 

5.2 Termination By Company Without Cause; Termination by Executive With Good Reason; Death or Disability 

(i) The Company may terminate Executive’s employment with the Company at any time without Cause
(as defined below). Executive may terminate his/her employment at any time for Good Reason, as defined below. Executive’s employment with the Company may also be terminated due to Executive’s death or Disability. For this purpose,
“Disability” shall mean that Executive is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last
for a continuous period of not less than 12 months, and shall be determined in the good faith and reasonable discretion of the Board. 

(ii) In the event Executive’s employment with the Company is terminated by the Company without
Cause, by the Executive for Good Reason, or by reason of Executive’s death or Disability, then provided such termination constitutes a “separation from service” (as defined under Treasury Regulation
Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from Service”), and provided that Executive remains in compliance with the terms of this
Agreement, the Company shall provide Executive with the following Severance Benefits: 
 (a) The
Company shall pay Executive, as severance, the equivalent of six (6) months of Executive’s base salary in effect as of the date of Executive’s employment termination (without taking into account any reduction in salary constituting
Good Reason), subject to standard payroll deductions and withholdings (the “Severance”). The Severance will be paid as a continuation on the Company’s regular payroll, beginning on the sixtieth (60th) day following Executive’s Separation from Service, provided the Separation Agreement (as discussed in Paragraph 6) has become effective. 

(b) The Company shall pay Executive a pro-rata bonus through
the date of termination, which bonus shall be paid only to the extent earned based on actual Company performance, not to exceed 100% of the target (with any individual performance component deemed achieved), on the date in the year following
termination on which bonuses are paid to other senior executives of the Company (but in any event no later than March 15 of such year), provided the Separation Agreement (as discussed in Paragraph 6) has become effective (the “Pro-Rata Bonus Payment”). 

  
 3 

 (c) The Company shall pay Executive any annual bonus
earned with respect to the year preceding the year of termination, if not already paid by the date of termination, which amount shall be paid on the sixtieth (60th) day following Executive’s
Separation from Service, provided the Separation Agreement (as discussed in Paragraph 6) has become effective (the “Prior Year Bonus Payment”). 

(d) The vesting of any of the Executive’s unvested restricted shares and options, including the
Option, shall be accelerated by one (1) quarter, such that 8.33% of the then-unvested restricted shares and options shall be deemed immediately vested and exercisable as of Executive’s last day of employment (the “Accelerated
Vesting”). 
 (e) The Company shall reimburse Executive the amount of any COBRA
continuation premium payments made by Executive (the “COBRA Premiums”) through the period (the “COBRA Premium Period”) starting on Executive’s Separation from Service and ending on the earliest to occur of:
(i) six (6) months following Executive’s Separation from Service; (ii) the date Executive becomes eligible for group health insurance coverage through a new employer; or (iii) the date Executive ceases to be eligible for COBRA
continuation coverage for any reason, including plan termination. In the event Executive becomes covered under another employer’s group health plan or otherwise ceases to be eligible for COBRA during the COBRA Premium Period, Executive must
immediately notify the Company of such event. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA Premiums without a substantial risk of violating applicable law (including, without
limitation, Section 2716 of the Public Health Service Act), the Company instead shall pay to Executive, on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including
premiums for Executive and Executive’s eligible dependents who have elected and remain enrolled in such COBRA coverage), subject to applicable tax withholdings (such amount, the “Special Cash Payment”), for the remainder of the
COBRA Premium Period. Executive may, but is not obligated to, use such Special Cash Payments toward the cost of COBRA premiums. 

5.3 Resignation by the Executive Without Good Reason; Termination by the Company for Cause 

(i) The Company may terminate Executive’s employment with the Company at any time for Cause and
Executive may resign at any time. 
 (ii) If Executive resigns or the Company terminates
Executive’s employment for Cause, then (i) Executive will no longer vest in additional unvested portions in the Option, (ii) all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to
amounts already earned), and (c) Executive will not be entitled to Severance, the Pro-Rata Bonus Payment, the Prior Year Bonus Payment, COBRA Premiums, Special Cash Payments, or Accelerated Vesting. In
addition, Executive shall resign from all positions and terminate any 

  
 4 

 relationships as an employee, advisor, officer or director with the Company and any of its
affiliates, each effective on the date of termination.  
 6. Conditions to Receipt of Severance, Pro-Rata Bonus Payment, Prior Year Bonus Payment, COBRA Premiums, Special Cash Payments and Accelerated Vesting . The receipt of Severance, the Pro-Rata Bonus Payment, the
Prior Year Bonus Payment, COBRA Premiums, Special Cash Payments, and Accelerated Vesting will be subject to Executive signing and not revoking a separation agreement and release of claims in a form reasonably satisfactory to the Company (the
“Separation Agreement”). No Severance, the Pro-Rata Bonus Payment, the Prior Year Bonus Payment, COBRA Premiums, Special Cash Payments, or Accelerated Vesting will be paid or provided until the
Separation Agreement becomes effective. Executive shall also resign from all positions and terminate any relationships as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the date of
termination. 
  

	 	7.	 Benefits in Connection with a Change of Control. 

7.1 Termination of Employment in Connection with a Change of Control. If there is a Change of Control
(as defined below) and (i) Executive’s employment is terminated Without Cause (as defined below), or (ii) Executive terminates his/her employment with Good Reason (as defined below), in either case within three months prior to, or 24
months following the effective date of the Change of Control, and provided a Separation Agreement (as discussed in Section 6) has become effective, then, in substitution for any benefits provided in Section 5.2, Executive shall be entitled
to the following benefits: (A) a lump sum payment equal to the sum of (y) 12 months of Executive’s then-current annual Base Salary and (z) 100% of the current target bonus percentage of Executive’s current annual Base Salary, to be
made not later than 60 days following Executive’s date of termination; and (B) the amount of any COBRA continuation premium payments made by Executive during the twelve (12) month period following the date of termination, or the
period ending when Executive becomes eligible for comparable group medical benefits from another source (whichever comes first). For avoidance of doubt, under no circumstances shall Executive receive benefits under both this Section 7.1 and
Section 5.2. 
 7.2 Acceleration of Options; Change of Control. If the Company terminates
Executive’s employment with the Company without Cause, or Executive resigns for Good Reason, in either case within three (3) months prior to, or twenty-four (24) months following the closing of a Change of Control (as defined below),
then in addition to the benefits set forth in Section 7.1 and pursuant to the terms of Section 6, the Company will fully accelerate the vesting of the Options and the RSU, as well as any other equity interests granted to Executive, such
that 100% of the then-unvested shares subject to the Options and the RSU (or other equity interests) will be deemed vested and exercisable as of Executive’s last day of employment. 

8. Section 409A. It is intended that all of the Severance Benefits and other payments payable under this Agreement
satisfy, to the greatest extent possible, the 

  
 5 

 exemptions from the application of Code Section 409A provided under Treasury
Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent
possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For purposes of Code Section 409A (including,
without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive’s right to receive any installment payments under this Agreement (whether severance payments,
reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to
the contrary in this Agreement, if Executive is deemed by the Company at the time of Executive’s Separation from Service to be a “specified employee” for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon
Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be “deferred compensation”, then to the extent delayed commencement of any portion of such payments is required in order to avoid a
prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to Executive prior to the earliest of (i) the expiration of the six-month period measured from the date of Executive’s Separation from Service with the Company, (ii) the date of Executive’s death or (iii) such earlier date as permitted under Section 409A
without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Paragraph shall be paid in a lump sum to Executive,
and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred. 
  

	 	9.	 Definitions. 

9.1 Change of Control. For purposes of this Agreement, “Change of Control” shall mean:
the acquisition of the Company or the Parent by another entity by means of any transaction or series of related transactions approved by the Board of Directors of the Parent to which the Parent is party (including, without limitation, any stock
acquisition, reorganization, merger or consolidation, but excluding any sale of stock for capital raising purposes) other than a transaction or series of transactions in which the holders of the voting securities of the Parent outstanding
immediately prior to such transaction continue to retain (either by such voting securities remaining outstanding or by such voting securities being converted into voting securities of the surviving entity), as a result of Ordinary Shares in the
Company held by such holders prior to such transaction, at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such transaction or series of
transactions. 
 9.2 Cause. For purposes of this Agreement, “Cause” for termination
will mean: (a) commission of any felony, or other crime involving dishonesty; (b) participation in any fraud against the Company; (c) material breach of Executive’s duties to the Company; (d) intentional and material damage
to any property 

  
 6 

 
of the Company; (e) misconduct or other violation of Company policy that causes material harm to the Company; (f) material breach of any material written agreement with the Company or
any material written Company policy; and (g) conduct by Executive which in the good faith and reasonable determination by the Board of Directors demonstrates gross unfitness to serve. An event described in (c), (d), (f) and (g) shall not
be treated as “Cause” until after Executive has been given written notice of such event, failure, conduct or breach and Executive fails to cure such event, failure, conduct or breach within 30 days from such written notice; provided,
however, that such 30-day cure period shall not be required if the event, failure, conduct or breach is incapable of being cured. 

9.3 Good Reason. For purposes of this Agreement, “Good Reason” for resignation will mean: (a) a
material reduction in Executive’s responsibilities, authorities, title or reporting relationship; (b) the requirement that Executive routinely report to work at a location that is greater than 50 miles from her current residence; or
(c) material breach by the Company of any material agreement between Executive and the Company, including this Agreement. In order for Executive to resign for Good Reason, Executive must provide written notice to the Company’s Board
or Chief Executive Officer within 90 days after the first occurrence of the event giving rise to Good Reason setting forth the basis for Executive’s resignation. Executive must then allow the Company at least 45 days from receipt of such
written notice to cure such event, and if such event is not reasonably cured by the Company within such 45-day period (the “Cure Period”), the Executive must then resign from all positions
Executive then holds with the Company not later than 90 days after the expiration of the Cure Period. 
 10.
Proprietary Information Obligations. As a condition of employment, Executive shall execute and abide by the Company’s standard form of Employee Proprietary Information, Inventions,
Non-Solicitation and Non-Competition Agreement (the “Confidentiality Agreement”) which contains restrictive covenants and prohibits unauthorized use or
disclosure of the Company’s confidential information and trade secrets, among other obligations. Executive agrees to review the Confidentiality Agreement and only sign it after careful consideration. 

 

	 	11.	 Outside Activities During Employment 

11.1 Non-Company Business. Except with the prior written
consent of the Company, which will not unreasonably be withheld, Executive will not during the term of Executive’s employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in
which Executive is a passive investor or received written clearance from the Company. Executive may engage in civic and not-for-profit activities, so long as such
activities do not materially interfere with the performance of Executive’s duties hereunder. 
 12. Dispute
Resolution. To ensure the timely and economical resolution of disputes that may arise in connection with Executive’s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action

  
 7 

 
arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, Confidentiality Agreement, or Executive’s employment, or the
termination of Executive’s employment, including but not limited to all statutory claims, with the exception of discrimination and harassment claims, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16 (the “FAA”), and to the fullest extent permitted by law, by final, binding and confidential arbitration by a single arbitrator conducted in New York, New York by Judicial Arbitration and
Mediation Services Inc. (“JAMS”) under the then applicable JAMS rules (at the following web address: https://www.jamsadr.com/rules-employment-arbitration/); provided, however, this arbitration provision shall not apply to
sexual harassment and discrimination claims to the extent prohibited by applicable law that is not preempted by the FAA (collectively, “Excluded Claims”). A hard copy of the rules will be provided to Executive upon request. By
agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. In addition, all claims, disputes, or causes of action under this
section, whether by Executive or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the
claims of any other person or entity. The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences
regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. The Company
acknowledges that Executive will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this Agreement shall be decided by a federal court in the State of
New Jersey. However, procedural questions which grow out of the dispute and bear on the final disposition are matters for the arbitrator. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of
the dispute and to award such relief as would otherwise be permitted by law; (b) issue a written arbitration decision, to include the arbitrator’s essential findings and conclusions and a statement of the award; and (c) be authorized
to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. Executive and the Company shall equally share all JAMS’ arbitration fees. To the extent JAMS does not collect or Executive
otherwise does not pay to JAMS an equal share of all JAMS’ arbitration fees for any reason, and the Company pays JAMS Executive’s share, Executive acknowledges and agrees that the Company shall be entitled to recover from Executive half of
the JAMS arbitration fees invoiced to the parties (less any amounts Executive paid to JAMS) in a federal or state court of competent jurisdiction. Except as modified in the Confidentiality Agreement, each party is responsible for its own
attorneys’ fees. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or
orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. To the extent applicable law prohibits mandatory arbitration of Excluded Claims and is not preempted by the FAA, in
the event Executive intends to bring multiple claims, including one or more Excluded Claims, the Excluded Claim(s) may be publicly filed with a court, 

  
 8 

 
while any other claims will remain subject to mandatory arbitration. 
  

	 	13.	 General Provisions. 

13.1 Notices. Any notices provided must be in writing and will be deemed effective upon the earlier of
personal delivery (including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll. 

13.2 Severability. Whenever possible, each provision of this Agreement will be interpreted in such
manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or
unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties. 

13.3 Waiver. Any waiver of any breach of any provisions of this Agreement must be in writing to be
effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 

13.4 Complete Agreement. This Agreement, together with the Confidentiality Agreement, constitutes the
entire agreement between Executive and the Company with regard to this subject matter and is the complete, final, and exclusive embodiment of the Parties’ agreement with regard to this subject matter. This Agreement is entered into without
reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. It is entered into without reliance on any promise or representation
other than those expressly contained herein, and it cannot be modified or amended except in a writing signed by a duly authorized officer of the Company. 

13.5 Counterparts. This Agreement may be executed in separate counterparts, any one of which need not
contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. 

13.6 Headings. The headings of the paragraphs hereof are inserted for convenience only and shall not be
deemed to constitute a part hereof nor to affect the meaning thereof. 
 13.7 Successors and Assigns.
This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of his/her duties
hereunder and he/she may not assign 

  
 9 

 
any of his/her rights hereunder without the written consent of the Company, which shall not be withheld unreasonably. 

13.8 Tax Withholding and Indemnification. All payments and awards contemplated or made pursuant to this
Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any
guarantees concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of
all payments and awards made pursuant to the Agreement. 
 13.9 Insurance and Indemnification. The
Company agrees to indemnify Executive in accordance with Company policy and applicable laws with respect to any acts or omissions Executive may have committed in his/her capacity as an office holder of the Company, and to include his/her in the
Company’s existing D&O insurance policy in accordance with Company policy and applicable laws. 

13.10 Choice of Law. All questions concerning the construction, validity and interpretation of this
Agreement will be governed by the laws of the State of New Jersey. 
 [Signature Page Follows] 

  
 10 

 IN WITNESS
WHEREOF, the Parties have executed this Agreement on the Effective Date. 
  

			
	UROGEN PHARMA, INC.
		
	 By:
	 	 /s/ Liz Barrett

		 	 Liz Barrett

		 	 Chief Executive Officer

  

			
	EXECUTIVE
	
	             /s/ Dong
Kim

	             
	 	Dong Kim

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]